Across TCGA pan-cancer cohorts, C2orf88 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C2orf88 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C2orf88 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated C2orf88 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where C2orf88 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	1.000	0.433	.007	36	view →
LSCC	OS	Tertile	All	0.945	0.683	<.001	13	view →
PDAC	OS	Tertile	III,IV	0.706	0.235	.006	7	view →
CCRCC	OS	Median	IV	0.785	0.123	.014	6	view →
LUAD	OS	Median	All	0.872	1.000	.027	1	view →
HNSC	DFS	Quartile	II,III,IV	0.495	0.857	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: C2orf88 tumor-vs-normal RNA expression · all C2orf88 data types